Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

KKR & CO. INC.

(KKR)
  Report
Delayed Nyse  -  04:00 2022-12-06 pm EST
49.05 USD   -1.05%
03:53aKKR to Acquire Medical Care Products Manufacturer Clinisupplies
MT
02:31aKKR to acquire Clinisupplies to accelerate growth and help build a leading international chronic care medical devices platform
BU
12/05Vodafone CEO to leave after frustrating four years for shareholders
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

A consortium of financial investors including Health Employees Superannuation Trust Australia and led by KKR & Co. Inc. cancelled the acquisition of Ramsay Health Care Limited.

09/26/2022 EST

A consortium of financial investors including Health Employees Superannuation Trust Australia and led by KKR & Co. Inc. (NYSE:KKR) made a non-binding, indicative and conditional proposal to acquire Ramsay Health Care Limited (ASX:RHC) for AUD 20 billion on April 20, 2022. As per the transaction, consortium made the offer to acquire shares at AUD 88 per share less any ordinary or special dividends paid to shareholders after the date of offer (including the ordinary dividend of AUD 0.485 per share paid on March 31, 2022). Ramsay Health Care Limited shareholders would have the option to receive part of the consideration in unlisted scrip in the Consortium holding entity. As per the alternative proposal dated August 25, 2022, Ramsay shareholders would be able to elect to receive cash consideration of AUD 88 cash per share for their first 5,000 Ramsay shares, the consideration for each Ramsay share in excess of 5,000 shares would be AUD 78.20 cash and approximately 0.22 Ramsay Santé shares. Approximately 18% of Ramsay shares would be eligible to receive AUD 88 cash per share and approximately 82% of shares would receive cash and Ramsay Santé shares as consideration. The transaction is subject to number of conditions including satisfactory due diligence, no disposal of any of Ramsay's subsidiaries or properties, final approval of the Consortium's investment committee, entry into a scheme implementation deed on customary terms and conditions, regulatory approvals (including Foreign Investment Review Board) and Ramsay shareholder approval. Ramsay shareholders do not need to take any action in relation to the transaction at this stage. Ramsay has appointed UBS AG, Australia Branch and Nicole Pedler and Tony Damian of Herbert Smith Freehills as financial and legal advisors respectively. Goldman Sachs acted as a financial advisor to Ramsay Healthcare.

A consortium of financial investors including Health Employees Superannuation Trust Australia and led by KKR & Co. Inc. (NYSE:KKR) cancelled the acquisition of Ramsay Health Care Limited (ASX:RHC) on September 26, 2022.


ę S&P Capital IQ 2022
Stocks mentioned in the article
ChangeLast1st jan.
KKR & CO. INC. -1.05% 49.05 Delayed Quote.-33.46%
RAMSAY HEALTH CARE LIMITED -0.54% 66.05 Delayed Quote.-7.64%
All news about KKR & CO. INC.
03:53aKKR to Acquire Medical Care Products Manufacturer Clinisupplies
MT
02:31aKKR to acquire Clinisupplies to accelerate growth and help build a leading internationa..
BU
12/05Vodafone CEO to leave after frustrating four years for shareholders
RE
12/02ContourGlobal takeover by KKR to have court hearing in December
AN
12/02UK's ContourGlobal Secures Antitrust, Regulatory Clearances for KKR Takeover
MT
12/01Jennifer Garner, John Legend attend lavish U.S. state dinner for France's Macron
RE
12/01KKR Announces New Managing Directors
BU
12/01KKR Announces New Managing Directors, Effective January 1, 2023
CI
11/30KKR Concludes Tender for Hitachi Transport System
MT
11/30KKR Reportedly to Sell Food Delivery Brands
CI
More news
Analyst Recommendations on KKR & CO. INC.
More recommendations
Financials (USD)
Sales 2022 6 855 M - -
Net income 2022 -1 309 M - -
Net Debt 2022 6 423 M - -
P/E ratio 2022 -32,3x
Yield 2022 1,26%
Capitalization 42 238 M 42 238 M -
EV / Sales 2022 7,10x
EV / Sales 2023 6,27x
Nbr of Employees 3 238
Free-Float 86,2%
Chart KKR & CO. INC.
Duration : Period :
KKR & Co. Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KKR & CO. INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Last Close Price 49,05 $
Average target price 62,79 $
Spread / Average Target 28,0%
EPS Revisions
Managers and Directors
Joseph Yong Bum Bae Co-Chief Executive Officer & Director
Scott Charles Nuttall Co-Chief Executive Officer & Director
Robert H. Lewin Treasurer & Head-Corporate Development
Henry R. Kravis Executive Co-Chairman
George Rosenberg Roberts Executive Co-Chairman
Sector and Competitors
1st jan.Capi. (M$)
KKR & CO. INC.-33.46%44 993
BLACKSTONE INC.-34.18%59 764
APOLLO GLOBAL MANAGEMENT, INC.-12.69%39 058
LEGAL & GENERAL PLC-14.25%18 447
FRANKLIN RESOURCES, INC.-18.63%13 613
ARES MANAGEMENT CORPORATION-10.89%13 440